Listen
REVATIO
-
Opinions on drugs -
Posted on
Jan 05 2011
- Updated on
Feb 10 2011
Reason for request
Reassessment of actual clinical benefit and improvement in actual clinical benefit under article R-163-21 of the Social Security Code. Inclusion in the extension of indication for patients in functional class II.
-
Clinical Benefit
| Moderate |
The actual clinical benefit is moderate. |
Clinical Added Value
| minor |
The Transparency Committee considers that the proprietary drug REVATIO provides a minor improvement in actual clinical benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension, or pulmonary arterial hypertension associated with systemic collagen disease, for patients in functional class II or III. |
Documents
Contact Us
Évaluation des médicaments
